Tirzepatide (crude)
Tirzepatide (LY3298176) (crude) is the crude form of Tirzepatide (HY-P1731).Tirzepatide (LY3298176) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide exerts anti-apoptotic and pro-differentiation effects via the pAkt/CREB/BDNF cascade and miRNA in neurons; in the heart, it promotes BCAA catabolism and inhibits the mTOR pathway by mediating the dephosphorylation of BCKDHA; meanwhile, it effectively reduces insulin and leptin levels and suppresses inflammatory responses at the systemic level. Tirzepatide can be used for research on myocardial infarction, colon cancer, diabetes, diabetic cognitive impairment, neurodegeneration, diabetes-related neuropathy, and obesity.
For research use only. We do not sell to patients.
- CAS No.: 2023788-19-2
- Formula: C225H348N48O68
- Molecular Weight:4813.45
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Biological Activity
Description
IC50 & Target
|
GLP-1 |
mTOR |
In Vitro
Tirzepatide (LY3298176) (0.2 μM; 7 days) sodium has no effect on the proliferation of human neuroblastoma SHSY5Y cells exposed to normoglycemic or hyperglycemic conditions, and upregulates the expression of nerve growth markers, differentiation markers, and glucose transporters[2].
Tirzepatide (0.2 μM; 7 days) sodium reverses high glucose-induced apoptosis and significantly reduces the BAX/Bcl-2 protein ratio in SH-SY5Y cells[2].
Tirzepatide (35-100 nM; 96 h) sodium exerts no direct effect on the proliferation of MC38 mouse colon cancer cells in vitro[3].
Tirzepatide sodium binds to BCKDHA, a key enzyme in branched-chain amino acid (BCAA) catabolism[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human neuroblastoma SHSY5Y cells (exposed to normal glucose (25 mM) or high glucose (150 mM))
-
Concentration:0.2 μM
-
Incubation Time:7 days
-
Result:Did not alter Ki-67 median fluorescence compared to untreated high glucose cells.
Had no significant effect on Ki-67 median fluorescence in normal glucose-exposed cells.
-
Cell Line:human neuroblastoma SHSY5Y cells (exposed to normal glucose (25 mM) or high glucose (150 mM))
-
Concentration:0.2 μM
-
Incubation Time:7 days
-
Result:Increased p-Akt protein levels (and p-Akt/AKT ratio), MAP2 protein levels, GAP43 protein level, and AGBL4 protein levels in normal glucose-exposed cells.
Prevented the high glucose-induced downregulation of p-Akt, MAP2, and GAP43 protein levels.
-
Cell Line:human neuroblastoma SHSY5Y cells (exposed to normal glucose (25 mM) or high glucose (150 mM))
-
Concentration:0.2 μM
-
Incubation Time:7 days
-
Result:Decreased miR-34a expression and increased miR-212 and miR-29c expression in normal glucose-exposed cells.
Reversed the high glucose-induced increase in miR-34a expression and reversed the high glucose-induced decrease in miR-212 and miR-29c expression in high glucose-exposed cells.
prevented the high glucose-induced downregulation of MAP2 and GAP43 mRNA expression in high glucose-exposed cells.
Did not affect AGBL4 mRNA or protein levels in high glucose-exposed cells.
-
Cell Line:MC38 murine colorectal cancer cells
-
Concentration:35, 70, 100 nM
-
Incubation Time:96 h
-
Result:Did not significantly alter proliferation rate of MC38 cells after 96 hours of incubation, as measured by cell number counts.
In Vivo
Tirzepatide sodium (1.35 mg/kg; i.p.; once weekly; for 15 weeks) induces mild metabolic and molecular changes in healthy rats without impairing spatial learning or memory abilities[1].
Tirzepatide sodium (10 nM/kg; s.c.; once daily; for 28 days) significantly reduces body weight, food intake, serum insulin and leptin levels, and indirectly inhibits tumor growth in a diet-induced obese (DIO) MC38 colon cancer mouse model[3].
Tirzepatide sodium (10 nM/kg; s.c.; once daily; for 14 days) significantly reduces body weight, food intake, serum insulin and leptin levels in diet-induced obese mouse models[3].
Tirzepatide sodium (10 nM/kg/day; i.p.; once daily; for 14 consecutive days) exerts protective effects in a mouse model of myocardial infarction (MI) induced by coronary artery ligation, including reducing mortality, decreasing myocardial infarction size, promoting branched-chain amino acid (BCAA) catabolism, and facilitating early fibrotic repair[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague Dawley (male, 7-8 weeks old, 180-200 g, high-fat diet + streptozotocin injection)[1]
-
Dosage:1.35 mg/kg
-
Administration:i.p.; once weekly; 8 weeks
-
Result:Significantly reduced fasting blood glucose and insulin levels.
Shortened escape latency and increased time spent in the target quadrant in the Morris water maze.
Decreased Aβ40 production and neuronal loss in the hippocampus.
Inhibited the mRNA expression of TNF-α, IL-6, IL-1β, and the phosphorylation of NF-κB.
-
Animal Model:Sprague Dawley (male, 7-8 weeks old, 180-200 g, normal diet-fed)[1]
-
Dosage:1.35 mg/kg
-
Administration:i.p.; once weekly; 8 weeks
-
Result:Induced a slight reduction in fasting blood glucose levels.
Slightly increased body weight.
Did not alter swimming speed in Morris water maze testing.
Caused minor reductions in hippocampal APP and BACE1 levels.
Had no significant effect on hippocampal Aβ40 levels or neuron density.
Slightly increased hippocampal PSD95 and SYT1 expression.
Increased density of stubby, mushroom-like, long, and filopodia-like dendritic spines.
Slightly reduced hippocampal mRNA levels of TNF-α, IL-6, and IL-1β.
Decreased phosphorylated NF-κB-positive cell percentage and phosphorylated IKKα levels.
Increased hippocampal p-IRS-1-S307, p-PI3K, p-AKT, p-GSK3β, and GSK3β levels.
-
Animal Model:C57BL/6 (male; diet-induced obesity via high-fat diet feeding)[3]
-
Dosage:10 nM/kg
-
Administration:s.c.; once daily; 14 days
-
Result:Reduced body weight relative to vehicle controls.
Reduced circulating glucose, insulin, leptin, and c-peptide levels in both fed and fasted states.
Eliminated the positive correlation between body weight and serum insulin levels seen in vehicle-treated controls.
-
Animal Model:C57BL/6 (male; diet-induced obesity via high-fat diet feeding; subcutaneous allograft of MC38 colon cancer cells)[3]
-
Dosage:10 nM/kg
-
Administration:s.c.; once daily; 28 days
-
Result:Caused a significant decrease in food intake and body weight.
Lowered glucose, insulin, leptin, and c-peptide levels in both fed and fasted states.
Significantly reduced MC38 tumor volume compared to the control group.
-
Animal Model:C57BL/6J wild-type (12-week-old male/female; myocardial infarction model via permanent left descending coronary artery ligation or concurrent low-BCAA diet intervention)[4]
-
Dosage:10 nM/kg/day
-
Administration:i.p.; once daily; 14 days (starting day 1 post-MI)
-
Result:Significantly improved long-term survival and reduced the incidence of cardiac rupture.
Decreased myocardial infarct size and improved left ventricular systolic function (increased LVEF).
Bound to BCKDHA and reduced its S293 phosphorylation, enhancing enzyme activity to promote cardiac BCAA catabolism and inhibit abnormal mTOR pathway activation.
Chemical Information
-
CAS No. 2023788-19-2
-
Appearance Solid
-
Molecular Weight 4813.45
-
Formula C225H348N48O68
-
Color White to off-white
-
Sequence
Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{Aib}-Leu-Asp-Lys-Ile-Ala-Gln-{C20 diacid-gamma-Glu-(AEEA)2-Lys}-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
-
Sequence Shortening
Y-{Aib}-EGTFTSDYSI-{Aib}-LDKIAQ-{C20 diacid-gamma-Glu-(AEEA)2-Lys}-AFVQWLIAGGPSSGAPPPS-NH2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (20.78 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Neurotoxicity Study
This protocol assesses in vitro neurotoxicity by combining neuronal viability, mitochondrial/metabolic activity, neurite outgrowth, and optional neuronal network function readouts. Calcein-AM or resazurin/PrestoBlue readouts estimate viable or metabolically active cells; βIII-tubulin immunofluorescence detects neuronal morphology and neurite networks; TMRE detects mitochondrial membrane potential; and MEA recordings detect functional changes in neuronal network activity.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
Purity & Documentation
-
Data Sheet (326 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Guo X, et al. Tirzepatide ameliorates spatial learning and memory impairment through modulation of aberrant insulin resistance and inflammation response in diabetic rats. Frontiers in pharmacology. 2023;14:1146960. [Content Brief]
[2]. Fontanella RA, et al. Tirzepatide prevents neurodegeneration through multiple molecular pathways. Journal of translational medicine. 2024 Jan 29;22(1):114. [Content Brief]
[4]. Chen M, et al. Glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist tirzepatide promotes branched chain amino acid catabolism to prevent myocardial infarction in non-diabetic mice. Cardiovascular research. 2025 Apr 29;121(3):454-467. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.2078 mL | 1.0388 mL | 2.0775 mL | 5.1938 mL |
| 5 mM | 0.0416 mL | 0.2078 mL | 0.4155 mL | 1.0388 mL | |
| 10 mM | 0.0208 mL | 0.1039 mL | 0.2078 mL | 0.5194 mL | |
| 15 mM | 0.0139 mL | 0.0693 mL | 0.1385 mL | 0.3463 mL | |
| 20 mM | 0.0104 mL | 0.0519 mL | 0.1039 mL | 0.2597 mL |
Keywords
- Tirzepatide (crude)
- 2023788-19-2
- GLP Receptor
- Insulin Receptor
- Apoptosis
- mTOR
- MC38 murine colorectal cancer cells
- GIPR
- BCKDHA
- mTOR signaling pathway
- glucagon-like peptide 1 receptor
- glucose-dependent insulinotropic polypeptide receptor
- branched-chain keto acid dehydrogenase E1 subunit α
- GLP-1R
- myocardial infarction
- SHSY5Y human neuroblastoma cells
- Inhibitor
- inhibitor
- inhibit